-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29

Benzinga·08/07/2026 19:21:37
Listen to the news
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $30 to $29.